CDK4 and melanoma: In addition, PTEN and FAT1 loss were recently found to be involved in mediating CDK4/6i resistance in breast cancer17,18, and the PRMT5-MDM4 signaling axis was reported to be involved in determining the response of melanoma to CDK4/6i treatment19.